Sign up for Table of Contents Alerts.
Email this page
Print this page
Bedside to Bench
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review
Vinay Gudena, Nitin Verma , Ginell Post, Michael Kizziah , Robert Fenning and Alberto J. Montero
volume 7 | issue 6
June 2008Pages: 810 - 813
Subscribe to this journal for $129/year
Malignant schwannomas or malignant peripheral nerve sheath tumors (MPNST) represent approximately 10% of all soft tissue sarcomas. Metastatic disease from chest wall MPNST is very rare. We present a case of a major clinical response to the tyrosine kinase inhibitor (TKI) sorafenib in a patient with metastatic MPNST. A 42-year-old female with a prior history of neurofibromas developed MPNST, which later metastasized to the lungs and brain. She was initially placed on sorafenib with significant clinical response to lung metastases. MPNST show high levels of Ras activity and hence these tumors are promising targets for TKIs. Studies are ongoing and the results are eagerly awaited regarding the responses to these medications and whether they can positively impact on the natural history of this disease.